US4338325A
Expired / Lapsed
US
⏱️ 0.0 years remaining
PGI2 Pharmacologically acceptable salts
Assignee: Pharmacia and Upjohn Co
•
Filing: 1980-10-27
•
Granted: 1982-07-06
•
Expires: 2000-10-27
Abstract
Abstract The present invention relates to PGI 2 pharmacologically acceptable salts, having pharmacological activity. Particularly, the compounds described herein are useful as platelet aggregation inhibitors.
Inventors
- 👤 Roy A. Johnson
- 👤 Frank H. Lincoln
- 👤 John E. Pike
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 15:03
CPC Classifications
C; C07; C07D; C07D307/00; C07D307/77; C07D307/93; C07D307/935; C07D307/937; C07C; C07C405/00; C07D311/00; C07D311/02; C07D311/94
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
18 words
A composition of matter consisting essentially of a pharmacologically acceptable salt of a compound of formula I ##STR3##
Claim 2
Dependent Claim
18 words
A composition of matter consisting essentially of a pharmacologically acceptable salt of a compound of formula I ##STR3##
Claim 3
Dependent Claim
15 words
A composition according to claim 1 wherein said pharmacologically acceptable salt is the benzyltrimethylammonium salt.
Claim 4
Dependent Claim
15 words
A composition according to claim 1 wherein said pharmacologically acceptable salt is the tetramethylammonium salt.
Claim 5
Dependent Claim
15 words
A composition according to claim 1 wherein said pharmacologically acceptable salt is the sodium salt.
Claim 6
Dependent Claim
12 words
A composition according to claim 4 in a free flowing powder form.
Claim 7
Dependent Claim
79 words
A parenteral pharmaceutical composition for inhibition of platelet aggregation characterized in being prepared from (1) a free flowing powder form of the sodium salt of PGI 2 , a compound of formula I ##STR4## and (2) a conventional pharmaceutical diluent for parenteral formulations, such that the sodium salt of PGI 2 is present in said composition at a concentration sufficient to inhibit platelet aggregation upon administration of a said composition in a predetermined volume or at a predetermined rate.
Claim 8
Dependent Claim
79 words
A parenteral pharmaceutical composition for inhibition of platelet aggregation characterized in being prepared from (1) a free flowing powder form of the sodium salt of PGI 2 , a compound of formula I ##STR4## and (2) a conventional pharmaceutical diluent for parenteral formulations, such that the sodium salt of PGI 2 is present in said composition at a concentration sufficient to inhibit platelet aggregation upon administration of a said composition in a predetermined volume or at a predetermined rate.
References Cited (Backward Citations)
US3598858A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-07-05 | 1986-01-04 | 1986-07-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-07-05 | 1990-01-04 | 1990-07-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-07-05 | 1994-01-04 | 1994-07-06 | $7700.00 | Window Closed / Lapsed |